Abstract Triple-negative breast cancer (TNBC) poses a formidable clinical challenge. Previous studies have suggested that intermittent cyclophosphamide (CTX) treatment can produce significant anti-tumor effects while minimizing adverse side effects; however, the underlying mechanisms are only partially understood.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Ling
Contact Ling, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack